Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target

Author: Benzinga Newsdesk | April 18, 2024 06:33am
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences (NASDAQ:IGMS) with a Neutral and maintains $12 price target.

Posted In: IGMS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist